PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES
Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, Secmeer G, Yetgin S. PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES. Pediatric Hematology And Oncology 2008, 25: 291-299. PMID: 18484473, DOI: 10.1080/08880010802016847.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmikacinAnti-Bacterial AgentsBacteriaBacterial InfectionsCarbapenemsChildChild, PreschoolDrug Therapy, CombinationEnzyme InhibitorsFemaleHumansLeukemia, Myeloid, AcuteMaleNeutropeniaPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationPrecursor Cell Lymphoblastic Leukemia-LymphomaConceptsFebrile neutropenic episodesDuration of feverPiperacillin/tazobactamCarbapenem monotherapyNeutropenic episodesHematological malignanciesFebrile neutropeniaEmpirical treatmentInitial empirical regimenInfection-related mortalityPediatric hematological malignanciesChildhood hematological malignanciesAcute lymphoblastic leukemiaAcute myeloblastic leukemiaAmikacin combinationEmpirical regimenPTA groupCarbapenem groupLymphoblastic leukemiaTreatment modificationAntimicrobial therapyClinical trialsTreatment successAdditional antibioticsCommon cause